Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: Private, Subsidiary

Established: 2004-07-08

Employees: -

Market Cap: -

Website: http://www.pinganzhengxing.com

Clinical Trials

Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients

Phase 2

Conditions: Metastatic Breast Cancer

Interventions: Drug: low-dose-bevacizumab/pemetrexed
Drug: Treatment of physician's choice

First Posted Date: 2016-07-12

Last Posted Date: 2016-07-12

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 120

Registration Number: NCT02829008

Locations: 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China

The Effect of Zhen Qi Shen Capsule Combined With Yu Yi Kang on Breast Cancer and Lung Cancer Patients With Chemotherapy

Not Applicable

Conditions: Breast Cancer
Lung Cancer

Interventions: Dietary Supplement: zhen qishen capsule and Oral Supplement of Yuyikang
Dietary Supplement: zhen qishen capsule placebo and Oral Supplement of Yuyikang placebo
Radiation: chemotherapy
Other: nutrition education

First Posted Date: 2016-05-13

Last Posted Date: 2016-05-13

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 300

Registration Number: NCT02771756

Locations: 🇨🇳
National Cancer Institute, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Apatinib
Drug: Oral Vinorelbine

First Posted Date: 2016-05-11

Last Posted Date: 2019-06-19

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT02768415

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients

Conditions: Breast Cancer

Interventions: Drug: Exemestane
Drug: Letrozole
Drug: Anastrozole

First Posted Date: 2016-05-06

Last Posted Date: 2019-05-13

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 500

Registration Number: NCT02765373

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: S-1
Drug: Oxaliplatin
Drug: Trastuzumab
Drug: Docetaxel

First Posted Date: 2016-04-01

Last Posted Date: 2022-08-17

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 180

Registration Number: NCT02725424

Locations: 🇨🇳
Chinese Academy of Medical Sciences, Beijing, Beijing, China

Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC

Phase 3

Conditions: Carcinoma, Small Cell
Lung Neoplasms

Interventions: Radiation: hypofractionated concurrent chemoradiotherapy
Radiation: conventionally fractionated concurrent chemoradiotherapy

First Posted Date: 2016-02-23

Last Posted Date: 2018-01-02

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 860

Registration Number: NCT02688036

Locations: 🇨🇳
Cancer Insititute and Hosiptal of Chinese Academy of Medical Sciences, Beijing, China

Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer

Phase 2

Conditions: Colorectal Cancer

Interventions: Drug: oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1

First Posted Date: 2016-02-23

Last Posted Date: 2016-02-23

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 50

Registration Number: NCT02688023

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Comparable Study of Different Thoracic Radiotherapy Regimens for Extensive Stage Small Cell Lung Cancer

Not Applicable

Conditions: Carcinoma, Small Cell
Lung Neoplasms

Interventions: Radiation: high-dose TRT
Radiation: standard-dose TRT

First Posted Date: 2016-02-05

Last Posted Date: 2019-04-04

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 186

Registration Number: NCT02675088

Locations: 🇨🇳
Cancer Insititute and Hosiptal of Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases

Phase 2

Completed

Conditions: Brain Metastases

Interventions: Radiation: Fractionated Stereotactic Radiotherapy
Drug: Temozolomide

First Posted Date: 2016-01-13

Last Posted Date: 2017-06-06

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 65

Registration Number: NCT02654106

Locations: 🇨🇳
Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Randomized Phase III Study of Adjuvant Chemotherapy With or Without Chemo-radiotherapy in Patients With Local Advanced Gastric Cancer After D2 Resection.

Phase 3

Conditions: Gastric Cancer

Interventions: Drug: Adjuvant chemotherapy for active comparator group
Radiation: Adjuvant Concurrent Chemo-radiotherapy
Drug: Adjuvant chemotherapy for experimental group

First Posted Date: 2016-01-07

Last Posted Date: 2016-01-07

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 588

Registration Number: NCT02648841

Locations: 🇨🇳
Cancer Hospital, Chinese academy of medical sciences, Bejing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy